HOW DIFFERENT ARE BRANDING STRATEGIES IN THE PHARMACEUTICAL INDUSTRY VERSUS FAST MOVING CONSUMER GOODS? Abstract The objective of this paper is to analyse the branding strategies used currently in the pharmaceutical industry and compare it to the best practices in Fast Moving Consumer goods. First the authors review the differences in the way branding is defined and organised in pharmaceuticals versus FMCG and identify why branding could be leveraged in the pharmaceutical industry to help
Premium Brand Brand management Branding
Getting the Marketing Mix Right Marketers have a wide array of selling tools at their disposal‚ but lack an effective method for predicting their success. Associate Professor Thomas J. Steenburgh and collaborators offer a new model for guiding their marketing investments. Key concepts include: Discrete choice models commonly used to evaluate marketing strategies often provide misleading results‚ leaving managers with the inability to accurately measure how they can get the best bang for their
Premium Marketing
Global Pharmaceutical Industry Analysis September 21 2009 Dibakar Mitra (P08017) I Manoj Joshi (B08026) Table of Contents EXECUTIVE SUMMARY 3 INTRODUCTION 4 ORIGIN AND EVOLUTION 5 ENVIRONMENT ANALYSIS (PEST) 7 STRUCTURAL INDUSTRY ANALYSIS (PORTER) 8 STRATEGIC ISSUES FACING THE INDUSTRY 11 STRATEGIC GROUPS IN THE INDUSTRY ACCORDING TO MARKET/DRUG/FUNCTIONING 15 PROCESS FLOW: IMPORTANT FUNCTIONS 16 STRATEGIC RESPONSES TO CHALLENGES: SIMPLE CORRELATION BETWEEN GROUP
Premium Pharmaceutical industry
www.pwc.com/pharma2020 Pharma 2020: Supplying the future Which path will you take? Pharmaceuticals and Life Sciences Previous publications in this series include: Published in June 2007‚ this paper highlights a number of issues that will have a major bearing on the industry by 2020. The publication outlines the changes we believe will best help pharmaceutical companies realise the potential the future holds to enhance the value they provide to shareholders and society alike
Premium Supply chain management Supply chain
GLAXOSMITHKLINE PHARMACEUTICALS GlaxoSmithKline plc is a global healthcare group engaged in the creation‚ discovery‚ development‚ manufacture and marketing of pharmaceutical and consumer health related products. The company operated in two segments: Pharmaceuticals (Prescription pharmaceuticals and vaccines)‚ and Consumer Healthcare. STRATEGIC BUSINESS UNIT – PHARMACEUTICALS MANUFACTURING AND MARKETING STRATEGIC GROUP FOR THE SBU – CONTRACT MANUFACTURING Company Information &
Premium Pharmaceutical industry
Exhibit 3.1 Strategic capabilities and competitive advantage Exhibit 3.2 Strategic capability: the terminology Exhibit 3.3 Sources of cost efficiency Exhibit 3.4 The experience curve Exhibit 3.5 Criteria for inimitability of strategic capabilities Analyzing Resources & Capabilities OUTLINE • The role of resources and capabilities in strategy formulation. • The resources of the firm • Organizational capabilities • Appraising the profit potential of resources and
Premium Knowledge Knowledge management Tacit knowledge
Is it possible to build better bureaucracies? Introduction The conception of bureaucracy is one of the most dominant notions in both organization theory and social science. It plays a significant role in modern society. (Clawson‚ 1980) Ever since the basic characteristics of bureaucracy were formulated by Max Weber‚ it has been suffered from derogatory remarks and harsh criticism and from various perspectives. For example‚ feminists such as Kathy Fergusson (1984)‚ liberals such as Mills (1951)
Premium Bureaucracy
Transnational Corporation in the world. Top 10 Pharmaceutical Companies based on 2012 pharma revenues (Contract Pharma‚ 2013) 1 Pfizer $51‚214 2 Novartis $46‚732 3 Merck $40‚601 4 Sanofi $38‚259 5 GlaxoSmithKline $33‚787 6 AstraZeneca $27‚973 7 Johnson & Johnson $25‚351 8 Abbott Laboratories $23‚133 9
Premium Strategic management Pharmaceutical industry
TERMINATOR TECHNOLOGY Genetic use restriction technology From Wikipedia‚ the free encyclopedia Jump to: navigation‚ search "Terminator gene" redirects here. For DNA transcription terminators‚ see Terminator (genetics). Genetic use restriction technology (GURT)‚ colloquially known as terminator technology or suicide seeds‚ is the name given to proposed methods for restricting the use of genetically modified plants by causing second generation seeds to be sterile. The technology was developed
Premium DNA Agriculture Genetically modified organism
Abstract The international accounting standards board (IASB) has replaced the international accounting standards committee (IASC) in 2001 and at the same time many standards of IFRS come from the International Accounting Standards which issued by IASC. After the new standards announce‚ the uptrend of globalisation has pushed more and more countries on their ways of adopting the international accounting standards. The drive for IASB is a British initiative and London is the headquarters for the IASB
Premium International Financial Reporting Standards Financial statements